Rigel Pharmaceuticals - RIGL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.96
  • Forecasted Upside: 374.91 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.83
▲ +0.15 (21.95%)

This chart shows the closing price for RIGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rigel Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RIGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RIGL

Analyst Price Target is $3.96
▲ +374.91% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Rigel Pharmaceuticals in the last 3 months. The average price target is $3.96, with a high forecast of $15.00 and a low forecast of $1.00. The average price target represents a 374.91% upside from the last price of $0.83.

This chart shows the closing price for RIGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in Rigel Pharmaceuticals. This rating has held steady since June 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2022CitigroupUpgradeNeutral ➝ BuyLow
11/4/2022BMO Capital MarketsLower TargetOutperform$4.00 ➝ $3.00Low
8/18/2022HC WainwrightBoost TargetBuy$7.00 ➝ $15.00Low
8/16/2022Piper SandlerBoost TargetNeutral$1.00 ➝ $2.00Low
8/9/2022CitigroupBoost Target$1.50Low
6/9/2022BMO Capital MarketsLower Target$7.00 ➝ $3.00High
6/9/2022B. RileyLower TargetNeutral$4.00 ➝ $1.25High
6/9/2022CitigroupDowngradeBuy ➝ Neutral$7.00 ➝ $0.80High
6/8/2022Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
6/8/2022Piper SandlerDowngradeOverweight ➝ Neutral$7.00 ➝ $1.00N/A
6/8/2022HC WainwrightLower TargetBuy$11.00 ➝ $7.00N/A
6/8/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral$6.00 ➝ $1.00N/A
3/23/2022B. RileyInitiated CoverageNeutral$4.00High
11/8/2021BMO Capital MarketsReiterated RatingBuy$8.00Low
9/28/2021HC WainwrightReiterated RatingBuy$11.00Medium
6/29/2021HC WainwrightReiterated RatingBuy$11.00Low
3/11/2021HC WainwrightReiterated RatingBuy$11.00Medium
2/18/2021HC WainwrightBoost TargetBuy$8.00 ➝ $11.00High
11/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
11/9/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
8/6/2020CitigroupBoost TargetBuy$7.00 ➝ $8.00High
7/9/2020HC WainwrightReiterated RatingBuy$8.00Medium
5/27/2020JPMorgan Chase & Co.Lower TargetOverweight$7.00 ➝ $6.00Low
12/18/2019HC WainwrightReiterated RatingBuy$8.00Low
12/9/2019BMO Capital MarketsLower TargetOutperform$11.00 ➝ $8.00Low
10/18/2019Cantor FitzgeraldReiterated RatingOverweightLow
9/26/2019JPMorgan Chase & Co.Reiterated RatingOverweight$7.00High
9/23/2019HC WainwrightSet TargetBuy$8.00High
5/7/2019Cantor FitzgeraldReiterated RatingBuy$7.00High
2/28/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$9.00 ➝ $7.00Medium
1/23/2019HC WainwrightReiterated RatingBuy$8.00Medium
1/23/2019Cantor FitzgeraldReiterated RatingBuy$9.00High
1/11/2019HC WainwrightSet TargetBuy$8.00Low
1/8/2019Cantor FitzgeraldReiterated RatingBuy$9.00Low
12/4/2018HC WainwrightSet TargetBuy$8.00High
12/3/2018Cantor FitzgeraldSet TargetBuy$9.00High
11/7/2018HC WainwrightSet TargetBuy$8.00High
10/29/2018HC WainwrightSet TargetBuy$8.00High
10/29/2018Cantor FitzgeraldSet TargetBuy$9.00High
10/11/2018HC WainwrightSet TargetBuy$8.00Low
10/5/2018HC WainwrightSet TargetBuy$8.00Medium
10/3/2018Cantor FitzgeraldReiterated RatingBuy$9.00Low
9/4/2018JPMorgan Chase & Co.Reiterated RatingOverweight$7.00Low
8/27/2018CitigroupInitiated CoverageBuy ➝ Buy$8.50High
8/9/2018HC WainwrightReiterated RatingBuy$8.00Low
8/8/2018Cantor FitzgeraldReiterated RatingBuy$9.00High
5/2/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$8.00 ➝ $10.00High
5/2/2018HC WainwrightLower TargetBuy ➝ Buy$8.00 ➝ $7.50High
5/1/2018Cantor FitzgeraldSet TargetOverweight ➝ Overweight$6.00 ➝ $9.00High
5/1/2018Piper Jaffray CompaniesBoost TargetOverweight$7.00 ➝ $8.00High
4/18/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$6.00 ➝ $8.00High
4/18/2018Jefferies Financial GroupBoost TargetBuy$7.00High
4/18/2018HC WainwrightSet TargetBuy$8.00High
4/17/2018Cantor FitzgeraldSet TargetBuy$6.00High
4/17/2018Piper Jaffray CompaniesBoost TargetOverweight$6.00 ➝ $7.00High
4/3/2018HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $6.70Medium
4/3/2018Cantor FitzgeraldReiterated RatingBuy$6.00High
3/7/2018HC WainwrightSet TargetBuy$7.00High
3/6/2018Cantor FitzgeraldReiterated RatingBuy$7.00High
2/2/2018HC WainwrightReiterated RatingBuy$7.00Low
1/19/2018HC WainwrightSet TargetBuy$7.00High
12/21/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$6.00Low
12/14/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$6.00High
12/11/2017HC WainwrightSet TargetBuy$7.00High
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
7/7/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/5/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/4/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 7 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Rigel Pharmaceuticals logo
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.83
Low: $0.82
High: $0.99

50 Day Range

MA: $0.85
Low: $0.67
High: $1.22

52 Week Range

Now: $0.83
Low: $0.64
High: $3.52

Volume

60,093,620 shs

Average Volume

1,367,546 shs

Market Capitalization

$144.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Rigel Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Rigel Pharmaceuticals in the last twelve months: B. Riley, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., Piper Sandler, StockNews.com, and TheStreet.
View the latest analyst ratings for RIGL.

What is the current price target for Rigel Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Rigel Pharmaceuticals in the last year. Their average twelve-month price target is $3.96, suggesting a possible upside of 374.9%. HC Wainwright has the highest price target set, predicting RIGL will reach $15.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $1.00 for Rigel Pharmaceuticals in the next year.
View the latest price targets for RIGL.

What is the current consensus analyst rating for Rigel Pharmaceuticals?

Rigel Pharmaceuticals currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RIGL, but not buy more shares or sell existing shares.
View the latest ratings for RIGL.

What other companies compete with Rigel Pharmaceuticals?

How do I contact Rigel Pharmaceuticals' investor relations team?

Rigel Pharmaceuticals' physical mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 624-1100 and its investor relations email address is [email protected] The official website for Rigel Pharmaceuticals is www.rigel.com. Learn More about contacing Rigel Pharmaceuticals investor relations.